U.S. Sen. Richard Blumenthal and researchers raise the alarm on how a federal medical research funding cap could impact "life ...

The money is developing treatments for diabetes, cancer and Alzheimer's disease. It could also mean a cure for a Ridgefield ...

Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...

Hansa Biopharma AB, "Hansa" or the "Company" , today published its Annual and Sustainability Reports for 2024. Peter Nicklin, Chair of the Board, Hansa Biopharma, said: "Hansa delivered several ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...

Shirley MacFarland’s weekly community column featuring news and notes from Brecksville, Broadview Heights, North Royalton and ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it ...

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...